ß-Thalassaemia major: Bone marrow versus peripheral blood stem cell transplantation

Journal of the Pakistan Medical Association

Volumn 58, Issue 3, 2008, Pages 107-110

  Irfan, Muhammad ^a   Hashmi, Khalil ^b   Adil, Salman ^c   Shamsi, Tahir ^a   Farzana, Tasneem ^a   Ansari, Saquib ^a   Panjwani, Vinodh ^a   Ahmed, Pervaiz ^b   Khan, Badshah ^b  

^a Bismillah Taqee Institute of Health Sciences and Blood Diseases Centre   (Pakistan)

^b National Institute of Heart Diseases National University of Medical Sciences   (Pakistan)

^c AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AZATHIOPRINE; BUSULFAN; CYCLOSPORIN; CYTARABINE; DEFEROXAMINE; FLUCONAZOLE; FLUDARABINE; HYDROXYUREA; IMMUNOGLOBULIN G; ISONIAZID; MEBENDAZOLE; METHOTREXATE; METRONIDAZOLE; PREDNISOLONE; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; COMPARATIVE STUDY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; INFANT; MORTALITY; PRESCHOOL CHILD; RISK FACTOR;

ADOLESCENT; BETA-THALASSEMIA; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; METHOTREXATE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RISK FACTORS; TREATMENT OUTCOME;

EID: 43749098742     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Pawliuk R, Bachelot T, Roftopoulos H, Kalberer C, Humphries RK, Bank A, et al. Retroviral vectors aimed at the gene therapy of human beta-globin gene disorders. Ann NYAcad Sci 1998; 850: 151-62.
2. Ahmed S, Saleem M, Modell B, Petrou M. Screening extended families for genetic hemoglobin disorders in Pakistan. N Engl J Med; 347: 1162-8.
3. Piga A, Longo F, Consolati A. Mortality and morbidity in thalassaemia with conventional treatment. Bone marrow transplant 1997; 19: 11-13.
4. Lucarelli G, Andreani M., Angelucci E. The Cure of the Thalassemia with Bone Marrow Transplantation. Bone marrow transplant; 2001: 28,S11-3.
5. Lucarelli G, Clift RA, Galemberti M, Polchi P, Angelucci E, Baronciani D, et al. Marrow Transplantation for Patients With thalassemia: results in class 3 Patients. Blood 1996; 87: 2082-8.
6. Locatelli F, Stefano PD. New insights into haematopoietic stem cell transplantation for patients with haemoglobinopathies. Br J Haematol 2004; 125: 3-11.
7. Hartmann O, Le corroller AG, Blaise D, Michon J, Philip I, Norol F, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997; 126: 600-7.
8. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702-9.
9. Salvin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation with lethal cytoreduction for the treatment of malignant and Nonmalignant Hematologic Diseases. Blood 1998; 91: 756-63
10. Sevilla J, Fernandez-Plaza S, Diaz MA, Madero L. Paediatric disease working party of the EBMT. Haematopoietic stem cell transplantation for bone marrow failure syndromes and thalassaemia. Bone Marrow transplant 2005; 35: 17-21.
11. Lucarelli G, Galimberti M, Polchi P, Angelveei E, Baronciani D, Giardiani C, et al. Bone Marrow Transplantation in patients with Thalassaemia: N engl J Med 1990; 322: 417-21.
12. Stary J, Locatelli F, Niemeyer CM. European working group on Myclodysplastic syndrome (EWOG - MDS) and Paediatric disease working party of the EBMT. Stem cell transplantation for Aplastic Anemia and Myelodysplastic Syndrome. Bone Marrow Transplant. 2005; 35: 13-6.
13. Dini G, Lamparelli T, Rondeili R, Lanino E, Barbanti M, Cost C, et al. Unrelated donor marrow transplantation for chronic myelogenous Leukemia. Br J Haematol 1998; 102: 544-52.
14. Li CK, Shing MM, Chik KW, Lee V, Leugn TF, Cheung AY, et al. Haematopoietic stem cell transplantation for thalassaemia major in Hong Kong: prognostic factors and outcome. Bone Marrow Transplant 2002; 29: 101-5.
15. Lawson SE, Roberts IA, Amrolia P, Dokal I, Szydlo R, Darbyshire PJ. Bone Marrow Transplantation for beta thalassaemia major: the UK experience in two pediatric centers. Br J Haematol 2003; 120: 289-95.
16. Chen YC, Lin KH, Huuang WS, Tang JL. Bone marrow transplantation in Taiwan: an overview. Bone Marrow Transplant 1994; 13: 705-8.
17. Copelan EA. Hematopoietic Stem-Cell Transplantation. N engl J Med 2006. 354: 1813-26.
18. Chandy M, Balasubramanian P, Ramachandran SV, Mathews V, George B, Denison D, et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in Thalassaemia - the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant 2005; 36: 839-45.
19. Storb R, Blume KG, O'Donnell MR, Chauncey T, Forman SJ, Deeg HJ, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogenic marrow transplantation : the experience in four centres. Biol Bone Marrow Transplant 2001; 7: 39-44.
20. Sodani P, Gaziev D, Polchi P, Erer B, Giardini C, Angelucci E, et al. New approach for bone marrow transplantation in patients with class 3 thalassaemia aged younger than 17 years. Blood 2004; 104: 1201-3.